Effect of Daratumumab based combination therapies in patients with relapsed refractory multiple myeloma
Latest Information Update: 08 Nov 2017
At a glance
- Drugs Daratumumab (Primary) ; Bortezomib; Dexamethasone; Pomalidomide
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 01 Nov 2017 Results (n=126) evaluating the effect of Daratumumab based combination therapies in patients with relapsed refractory multiple myeloma, were published in the American Journal of Hematology.
- 30 Jun 2017 New trial record
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology